Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960962 | 0.89 | MAP3K14 (0.36) | ALDH1A1MAP3K14MAPK14LMNATSHR | |
| SCHEMBL21960977 | 0.77 | MAP3K14 (0.34) | MAP3K14 | |
| SCHEMBL17438003 | 0.75 | KDM4E (0.40) | NR4A3ALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL3293316 | 0.73 | NR4A3 (0.38) | HCAR2NR4A3ALDH1A1KDM4CSMN1; SMN2 | |
| SCHEMBL21960976 | 0.72 | NPC1 (0.45) | SMN1; SMN2POLB | |
| SCHEMBL25623930 | 0.72 | ALDH1A1 (0.34) | NR4A3ALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL26135833 | 0.72 | ALKBH1 (0.37) | NR4A3ALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL21964587 | 0.71 | HCAR2 (0.38) | HCAR2MAP3K14MAPK1TSHR | |
| SCHEMBL25108322 | 0.69 | KDM4E (0.30) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL772194 | 0.68 | S1PR1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | HCAR2 1525/4885NR4A3 1137/4885ALDH1A1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.